HEC169096 in Participants With Advanced Solid Tumors

Summary

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.

Timeline

Start

2022-10-21

Primary completion

2026-12-30

Completion

2027-08-30

Drugs

Indications